Business Context and Reporting Period
This Form 8-K is a Current Report filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 8, 2009. The registrant is incorporated in Delaware and headquartered in Annapolis, Maryland. The report addresses a change in the schedule for a conference call regarding the company's recombinant protective antigen anthrax vaccine program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding a corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the rescheduling of a conference call intended to provide an update on the company's anthrax vaccine program. The call was moved to Wednesday, December 9, 2009, at 9:00 a.m. Eastern Time.
Guidance, Outlook, and Risks
- Management Commentary: The company issued a press release (Exhibit 99.1) to notify stakeholders of the new conference call time.
- Regulatory Note: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly referenced.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata referenced Altimmune, Inc.
- Confirm the new conference call date and time (December 9, 2009, 9:00 a.m. ET) via the press release in Exhibit 99.1.
- Review the actual content of the conference call or subsequent filings for financial data, as this 8-K contains none.